Evidence map›Paper›PMID 31841553›Full record

ArticlePLoS pathogens2019

Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans.

Nelson R Wu, Nathan I Nicely, Esther M Lee, Rachel K Reed, Brian E Watts, Fangping Cai, William E Walkowicz, Baptiste Aussedat, Julia A Jones, Amanda Eaton and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Conformational diversity facilitates antibody mutation trajectories and discrimination between foreign and self-antigens.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Nelson R WuDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0002-2612-8729
Nathan I NicelyDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0002-0025-2377
Esther M LeeDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Rachel K ReedDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Brian E WattsDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Fangping CaiDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
William E WalkowiczDepartment of Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.ORCID 0000-0002-7961-1175
Baptiste AussedatDepartment of Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.ORCID 0000-0002-8828-8963
Julia A JonesDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0002-4900-5406
Amanda EatonDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0003-3064-2947
Ashley M TramaDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
S Munir AlamDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
David C MontefioriDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0003-0856-6319
Barton F HaynesDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Kevin O SaundersDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0001-7399-7954
Duke Medical Center · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
HIV-1 vaccine-elicited antibodies target envelope glycansR01AI120801 · NIAID · DUKE UNIVERSITY · PI SAUNDERS, KEVIN O · 2015 to 2024
$7.5M
NCI NIH HHS P30 CA008748NIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI120801NIAID NIH HHS UM1 AI100645
6 · The paper itself

Abstract

Viral glycoproteins are a primary target for host antibody responses. However, glycans on viral glycoproteins can hinder antibody recognition since they are self glycans derived from the host biosynthesis pathway. During natural HIV-1 infection, neutralizing antibodies are made against glycans on HIV-1 envelope glycoprotein (Env). However, such antibodies are rarely elicited with vaccination. Previously, the vaccine-induced, macaque antibody DH501 was isolated and shown to bind to high mannose glycans on HIV-1 Env. Understanding how DH501 underwent affinity maturation to recognize glycans could inform vaccine induction of HIV-1 glycan antibodies. Here, we show that DH501 Env glycan reactivity is mediated by both germline-encoded residues that contact glycans, and somatic mutations that increase antibody paratope flexibility. Only somatic mutations in the heavy chain were required for glycan reactivity. The paratope conformation was fragile as single mutations within the immunoglobulin fold or complementarity determining regions were sufficient for eliminating antibody function. Taken together, the initial germline VHDJH rearrangement generated contact residues capable of binding glycans, and somatic mutations were required to form a flexible paratope with a cavity conducive to HIV-1 envelope glycan binding. The requirement for the presence of most somatic mutations across the heavy chain variable region provides one explanation for the difficulty in inducing anti-Env glycan antibodies with HIV-1 Env vaccination.

Indexed as

AIDS VaccinesAnimalsAntibodies, NeutralizingBase Sequenceenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV InfectionsHumansMutationPolysaccharidesAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesPolysaccharides

Identifiers

PMID31841553
PMCPMC6936856
OpenAlexW2996241347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.